DRONEDARONE (dronedarone) by Aurobindo Pharma is unknown. Approved for hospitalization for atrial fibrillation (af) in patients in sinus rhythm with a history of paroxysmal, persistent af (, atrial fibrillation.
Drug data last refreshed 1mo ago
unknown. Dronedarone has antiarrhythmic properties belonging to all four Vaughan-Williams classes, but the contribution of each of these activities to the clinical effect is unknown.
Worked on DRONEDARONE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation
Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence
Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects
Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation